Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Seeking Alpha
2025 revenue grew 8% to $655 million, but new indications like NSCLC and mesothelioma contributed minimally and face adoption challenges. Gross margins declined to 73–74%, highlighting economic and execution difficulties as NVCR expands beyond its core market. Upcoming 2026 catalysts include PANOVA-4 data, but commercial prospects outside glioblastoma remain highly uncertain amid rising expenses. Mark Kostich/iStock via Getty Images NovoCure Limited ( NVCR ) is a stock that I've covered since 2017. The company markets tumor-treating fields (TTFields) for the treatment of cancer. Over the last few years, in my view, it's become obvious that TTFields don't have much utility This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensati
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.MarketBeat
- NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at HC Wainwright from $42.00 to $39.00. They now have a "buy" rating on the stock.MarketBeat
- Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company UpdateBusiness Wire
- NovoCure (NASDAQ:NVCR) was given a new $20.00 price target on by analysts at Evercore ISI.MarketBeat
- Novocure to Present at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
NVCR
Earnings
- 10/30/25 - Beat
NVCR
Sec Filings
- 1/12/26 - Form 4
- 1/12/26 - Form 8-K
- 1/8/26 - Form 5
- NVCR's page on the SEC website